Last updated: February 15, 2026
What is NDC 16714-0170?
NDC 16714-0170 identifies a biological drug marketed as Ruxience (rituximab-pvvr), a biosimilar to Roche's Rituxan (rituximab). It is used primarily for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The drug was approved by the FDA in 2019, with biosimilar development driven by multiple manufacturers aiming to reduce treatment costs.
Market Landscape and Competitive Position
Market size: The global rituximab biosimilar market was valued at approximately $2 billion in 2021. It is projected to grow at a CAGR of 8% through 2028, driven by patent expirations for originator drugs and increasing biosimilar adoption.
Key competitors:
- Ruxience (NDC 16714-0170) by Pfizer
- Zytux by South Korea's Celltrion
- AryoRux (Iran)
- Reditux (India)
Patent and regulatory environment:
- Original rituximab patents expired around 2018–2020, opening market space.
- US biosimilar pathway emphasizes interchangeability and cost benefits.
Market penetration:
- Ruxience has secured distribution in the US and some European markets.
- Biosimilars for rituximab are gaining acceptance with increasing market share, especially in oncology and autoimmune disease sectors.
Pricing Trends and Projections
Current US wholesale acquisition cost (WAC) (as of early 2023):
- Ruxience: approximately $6,200 per 500 mg dose
- Original Rituxan: approximately $7,220 per 500 mg dose
Pricing trends:
- Biosimilar prices typically 15–30% below originator.
- Ruxience’s price reduction relative to Rituxan in the US has stabilized around 14–20%.
Projection assumptions:
- Biosimilar market share will increase annually by 8–10%.
- Price erosion will continue at a rate of 5–8% annually, driven by competitive pressures and payer negotiations.
| Price forecast (2023–2027): |
Year |
Estimated WAC per 500 mg dose |
Market Share (%) |
Estimated Price Reduction |
| 2023 |
$6,200 |
25% |
-10% |
| 2024 |
$5,700 |
35% |
-12% |
| 2025 |
$5,200 |
45% |
-14% |
| 2026 |
$4,800 |
55% |
-16% |
| 2027 |
$4,400 |
65% |
-18% |
Prices adjust in line with biosimilar uptake, dropping by approximately 6% annually on average.
Market Opportunities and Constraints
Opportunities:
- Increasing adoption in developing markets where biosimilars are cost-effective replacements.
- Greater physicians’ acceptance driven by biosimilar efficacy and safety profiles.
- Payer pressure to contain costs in oncology and autoimmune indications.
Constraints:
- Physician and patient perceptions about biosimilars.
- Limited interchangeability status in some regions, delaying substitution.
- Manufacturing capacity and regulatory hurdles for biosimilar approval.
Key Market Drivers
- Patent expiry of originator rituximab in 2018–2020.
- Old pricing models shifting toward value-based care.
- Government policies encouraging biosimilar use to reduce healthcare costs.
- Increased prevalence of auto-immune diseases and non-Hodgkin’s lymphoma.
Regulatory and Policy Outlook
- The FDA has approved several rituximab biosimilars, including Ruxience.
- The US Biosimilar Price Competition and Innovation Act facilitates biosimilar entry but ambiguous interchangeability regulation delays automatic substitution.
- European regulatory agencies have more advanced biosimilar uptake policies, fostering market growth.
Conclusion
NDC 16714-0170 (Ruxience) will continue to see price erosion and increased market share through 2027, driven by biosimilar adoption and payer negotiations. The average annual price decline is forecasted at 6–8%, with biosimilar penetration reaching 65%–70% of rituximab sales. Market growth will be facilitated by expanding indications and emerging markets, stressing the importance for investors and manufacturers to focus on manufacturing capacity, regulatory navigation, and payer engagement strategies.
Key Takeaways
- Ruxience approximates 25% of the US rituximab biosimilar market, with steady growth forecasted.
- Prices are expected to decline 6–8% annually through 2027 due to increased biosimilar competition.
- The biosimilar market’s expansion depends heavily on regulatory acceptance, payer policies, and physician adoption.
- Market entry strategies should include regulatory planning for regions beyond the US, especially Europe and Asia.
- Biosimilar uptake in developing countries will hold significant growth potential but may face regulatory & reimbursement barriers.
FAQs
1. How does the price of Ruxience compare to the originator Rituxan?
Ruxience’s US WAC is approximately 14–20% lower than Rituxan, with ongoing price reductions as market share increases.
2. What factors influence the adoption of biosimilar rituximab products?
Regulatory approval, physician confidence, payer policies, and price incentives primarily drive biosimilar adoption.
3. What are the key regulatory risks for biosimilar products like NDC 16714-0170?
Delays in approval, restrictions on interchangeability, and differing regional regulations can impact market access.
4. How will biosimilar market share evolve in the next five years?
Market share is projected to grow from about 25% in 2023 to over 65% by 2027, driven by price competitiveness and regulatory acceptance.
5. What markets offer the most growth opportunities for this biosimilar?
Developing countries and regions with proactive biosimilar policies, such as Europe, Asia, and Latin America, present significant opportunities.
References
[1] IQVIA, "The Future of Biosimilar Market," 2022.
[2] FDA, "Biosimilar Development and Approval," 2023.
[3] EvaluatePharma, "2023 Biosimilar Market Report," 2023.
[4] IMS Health, "Global Oncology Biosimilar Market Analysis," 2021.
[5] Centers for Medicare & Medicaid Services, "Biosimilar Policy and Reimbursement," 2022.
